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It is now well established that glial cells not only provide mechanical and trophic support to neurons but can directly contribute to
neurotransmission, for example, by release and uptake of neurotransmitters and by secreting pro- and anti-inflammatorymediators.
This has greatly changed our attitude towards acute and chronic disorders, paving the way for new therapeutic approaches targeting
activated glial cells to indirectlymodulate and/or restore neuronal functions. A deeper understanding of themolecularmechanisms
and signaling pathways involved in neuron-to-glia and glia-to-glia communication that can be pharmacologically targeted is
therefore a mandatory step toward the success of this new healing strategy. This holds true also in the field of pain transmission,
where the key involvement of astrocytes andmicroglia in the central nervous system and satellite glial cells in peripheral ganglia has
been clearly demonstrated, and literally hundreds of signalingmolecules have been identified. Here, we shall focus on one emerging
signaling system involved in the cross talk between neurons and glial cells, the purinergic system, consisting of extracellular
nucleotides and nucleosides and their membrane receptors. Specifically, we shall summarize existing evidence of novel “druggable”
glial purinergic targets, which could help in the development of innovative analgesic approaches to chronic pain states.
1. Chronic Pain: Neurons Need Costars
to Be Sensitized
Several lines of evidence from basic pain research using
diverse animal models indicate that an aberrant excitability
of doreceptor agonists, such asrsal horn neurons evoked by
peripheral sensory inputs is at the basis of both neuropathic
and inflammatory pain [1, 2]. While neurons have long been
considered the only cell type involved in pain development
and transmission, recent studies have shown that patho-
logically altered neurotransmission requires communication
with glial cells [3].
Microglia show a long-term response to a wide range
of stimuli controlling physiological homeostasis, including
peripheral nerve injury (PNI). In response to PNI, microglia
activation in the spinal cord leads to cell hypertrophy,
increase in cell number, and altered gene expression [4–6]. By
responding to extracellular stimuli, activated glial cells evoke
various cellular responses, such as production and release
of bioactive factors including cytokines and neurotrophic
factors [7], which in turn lead to the hyperexcitability of
dorsal horn neurons and, consequently, to the development
of neuropathic pain.
Not only spinal microglia but also astrocytes are involved
in neuronal sensitization in the spinal cord. In fact, it has
been hypothesized that microglia sense nerve damage or
proalgogenic inputs from the periphery, and as a conse-
quence they release several mediators that either act directly
on dorsal horn neurons or promote reactive astrogliosis
[8]. Reactive astrogliosis is a typical double-edged sword
phenomenon, showing both neurotoxic and neuroprotective
features, depending upon the type of injury and the basal
conditions of the affected tissue [9]. This is possibly true also
in pain models, where both astrocyte-derived proalgogenic
and analgesic molecules have been detected [8].
Glial cells are directly involved in nociception not only in
the central nervous system (CNS), but also in the periphery.
In fact, a peculiar type of glial cells, named satellite glial
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cells (SGCs), is located in peripheral sensory ganglia, where
they enwrap neuronal bodies, thus constituting distinct
morphological and functional units [10]. In the past few
years, their central role in the development and maintenance
of chronic pain has been clearly demonstrated by several
authors, reporting an increased expression and release of
mediators such as interleukin-1𝛽 (IL-1𝛽) and tumor necrosis
factor alpha (TNF𝛼) [11, 12], as well as their increased gap
junction-mediated coupling following nerve injury [13]. In
response to chronic pain, SGCs also upregulate the expression
of glial fibrillary acidic protein (GFAP) and undergo cell
division [14, 15].
The currently established role of glial cells in nociception
suggests that the pharmacologicalmanipulation of their reac-
tivity might represent a groundbreaking analgesic strategy,
as an alternative to a classical “neuron-centric” approach.
It is therefore mandatory to identify the most promising
key signaling pathways contributing to glial cell reaction to
painful stimulation, which could be exploited pharmacolog-
ically. Here, we shall focus on the purinergic system, which
in recent years has emerged as one of the most innovative
and yet partially unexplored signaling systems controlling
glial cell function under various pathological conditions,
including pain. Far from being exhaustive in reviewing the
exponentially growing number of publications in this field,
this review aims at convincing the pain community that
extracellular nucleotides and nucleosides are fundamental
pro- and antinociceptive signals, mostly through their activ-
ity on peripheral and central glial cells.
2. Ionic Receptors Activated by Extracellular
Nucleotides: The P2X Receptor Family
Extracellular nucleotides, mostly ATP but possibly also
UTP, are costored in synaptic vesicles and actively released
during physiological or pathological (i.e., excitotoxic) neu-
rotransmission [16]. Glial sources of ATP have been also
demonstrated, which contribute to physiological cell-to-cell
communication [17]. Additionally, extracellular concentra-
tions of nucleotides increase severalfold at sites of tissue
damage, due to leakage of the intracellular nucleotide pool
and degradation of nucleic acids [16, 17].
P2X receptors are membrane ion channels that open in
response to the binding of extracellular ATP and elicit rapid
responses (<10ms), resulting in selective permeability toNa+,
K+, and Ca2+ cations [18]. In vertebrates, seven genes encode
P2X receptor subunits, which are 40–50% identical in their
amino acidic sequence. Each subunit has two transmembrane
domains, separated by an extracellular domain (∼280 amino
acids). Channels function as trimers of several subunits, and
the extracellular domain is the portion containing the bind-
ing sites for nucleotides. To date, 7 homomeric (P2X1, P2X2,
P2X3, P2X4, P2X5, P2X6, and P2X7), and 6 heteromeric
P2X receptors (P2X1/2, P2X1/4, P2X1/5, P2X2/3, P2X2/6, and
P2X4/6) have been identified, the latter showing specific
pharmacological differences compared to their homomerical
counterpart [18]. P2X receptors are differentially distributed
among the cell types in different brain areas. Peripheral
neurons mainly express the P2X3 and P2X2/3 receptor
subtypes, which are involved in pain and temperature per-
ception (see below) [19]. All P2X receptor subtypes can
modulate membrane action potential. They are expressed
either at the presynaptic level, regulating neurotransmitters
release through the modulation of intracellular levels of Ca2+
ions, or postsynaptically, where they interact with ionotropic
receptors (i.e., nicotinic; gamma-aminobutyric acid, GABA;
N-Methyl-D-Aspartate, NMDA) via Ca2+-dependent kinases
[16]. P2X receptors are involved in a variety of physiological
processes, including the modulation of cardiac rhythm and
contractility, vascular tone, platelet aggregation, macrophage
activation, apoptosis, neuron-glia communication, andmod-
ulation of nociception [20].
3. P2X Receptors and Chronic Pain: Not Only
a Matter of Neurons
Since the first publications demonstrating the involvement
of ATP in pain transmission [21], the expression levels
and functions of P2X receptors have been characterized
in neurons from dorsal root ganglia (DRG) and in the
trigeminal nerve [22]. All P2X receptor subtypes, with the
exception of P2X7, are expressed in sensory neurons; among
these, the P2X3 subtype showed the highest expression levels
[23]. To date, the most important P2X receptor subtypes
involved in pain transmission are (i) the P2X3 and P2X2/3
receptor subtypes, expressed by sensory neurons, (ii) the
P2X4 receptor, expressed by CNS microglia, and (iii) the
P2X7 receptor, expressed by CNS microglia and astrocytes
and by SGCs in sensory ganglia [24].
4. Neuronal P2X3 Receptors: Key
Players in Nociception
Although this review article is focused on glial purinergic
receptors involved in pain transmission, a brief summary
of data on neuronal P2X3 subtype, the most studied P2X
receptor subtype involved in nociception, cannot be omitted.
P2X3 receptors are selectively expressed at high levels in
nociceptive primary sensory neurons in trigeminal, nodose,
and dorsal root ganglia [25]. The selective expression of
P2X3 receptors in these areas involved in pain transmission
suggested that they may be crucial in processing pain signals,
and several studies have evaluated the relationships between
P2X3 receptors and pain sensation.
P2X3 receptors have been initially cloned and function-
ally characterized from rat DRG [26], showing their unique
expression in small and medium size sensory neurons and
their absence in large diameter neurons [27, 28]. On the other
hand, P2X3 has never been found to be expressed by glial
cells, by either immunohistochemical analysis or calcium
imaging [29]. P2X3 immunoreactivity has also been observed
in other structures indirectly involved in nociceptive trans-
mission, such as the nucleus of the solitary tract, and the
spinal trigeminal nucleus [30].
Anumber of in vitro and in vivo studies have evaluated the
relationships between P2X3 receptors and pain transmission.
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Local injection of P2X3 receptor agonists, such as ATP
or 𝛼,𝛽-methyleneATP, into the hind paws of rats induced
nociceptive behaviors and reduced thermal and mechanical
thresholds [31, 32]. During inflammation and chronic con-
striction injuries, ATP concentrations and neuronal expres-
sion of P2X3 receptors are upregulated in DRG, trigeminal
ganglion (TG), and spinal cord [33, 34]. In animal models of
inflammatory and neuropathic pain, P2X3 receptor knock-
out or its downregulation by antisense oligonucleotides or by
short interfering RNA significantly attenuated painful behav-
iors, including tactile allodynia and mechanical hyperalgesia
[35]. In addition, the nonselective P2X3 receptor antago-
nists TNP-ATP [2󸀠,3󸀠-O-(2,4,6 trinitrophenyl) adenosine-5󸀠-
triphosphate] and PPADS pyridoxal phosphate-6-azophenyl-
2󸀠,4󸀠 disulfonic acid reduced the excitability of DRG neurons
and neuropathic pain [36]. Overall, these findings suggest
that neuronal P2X3 receptors play a crucial role in the
development and maintenance of chronic pain.
Despite the above-mentioned results, more recent studies
have shown a transient decrease in P2X3 expression in a
model of partial damage of themental nerve (belonging to the
mandibular branch of the trigeminal nerve), or no significant
expression changes following resection of the lingual nerve
[37]. It is possible that these differences reflect the type of
lesion: after a constriction (i.e., application of a ligature) an
increase in the expression levels is observed, while nerve
injury or full axotomy leads to reduction or no changes of
receptor expression. More importantly, it has been observed
that variations in P2X3 expression levels are modulated at
different time points after the lesion; a transient decrease in
the expression was observed in the first two weeks after nerve
injury, followed by an increase during the following weeks,
paralleled by the increased expression of glial cell-derived
neurotrophic factor (GDNF) and the generation of new
neuronal branches (sprouting) in the damaged sensory areas
[38]. Therefore, the timing and the type of lesion are critical
for the observed results. Finally, it is also worth mentioning
that P2X3 receptors are involved in the mechanism of action
of known analgesics, as recently shown for the nonsteroidal
anti-inflammatory drug naproxen, which inhibits P2X3 acti-
vation in the TG [39]. Moreover, it is now emerging that
bioactive molecules contained in analgesic preparation from
traditional Chinese medicine (such as tetramethylpyrazine,
sodium ferulate, and puerarin) can inhibit P2X3-mediated
transmission in primary afferent neurons [40].
5. Glial P2X4 and P2X7 Receptors
Microglia-neuron communication is bidirectional, and sev-
eral lines of evidence implicate ATP as a critical signaling
molecule [41–43]. Microglia expression of P2X receptors is
restricted to the P2X4 and P2X7 subtypes [42, 44], whose
activation evokes current responses, increases intracellular
[Ca2+], and causes the release of signalingmolecules affecting
neuronal functions [45, 46].
The central role of P2X4 receptor subtype in neuropathic
pain was first reported by [47]. In this paper, authors showed
that intrathecal injection of TNP-ATP, acting as antagonist
at P2X1-4 receptor subtypes, reverted tactile allodynia in
nerve-injured rats. On the contrary, treatment with PPADS,
antagonist at P2X1-3, 5, and 7 but not at P2X4 receptor, had
no effect. Authors therefore concluded that the main P2X
receptor subtype involved in central responses to peripheral
nerve injury is the P2X4 receptor, and the development
and maintenance of tactile allodynia require its activation.
To confirm this hypothesis, targeting P2X4 receptors with
antisense oligonucleotides [47] or the genetic deletion of
the P2rx4 gene [48] significantly attenuated nerve injury-
induced pain phenotypes. Moreover, the development of
tactile allodynia correlated with a progressive increase in
spinal P2X4 receptor expression, which is generally low in
na¨ıve CNS [48].
Further immunohistochemical analysis of wild-type (wt)
mice, and studies on transgenic mice selectively expressing
the green fluorescent protein in microglial cells revealed
that this cell population rather than neurons or astrocytes
was expressing the P2X4 receptor subtype [48] and that the
increase in P2X4 receptor expression temporally correlated
with the development of tactile allodynia. P2X4 receptor
upregulation was a consequence, rather than a cause of
microglia activation; in fact, preventing the increase in P2X4
receptor did not affect the expression of protein markers
of microglia activation, such as complement receptor 3 or
the ionized calcium binding adaptor molecule-1 (Iba-1) [47,
48]. Interestingly, activation of microglial P2X4 receptor is
sufficient to elicit pain, since the intrathecal injection of P2X4
receptor-stimulated cultured microglia induced mechanical
allodynia in na¨ıve animals [41, 47, 49]. Taken together,
pharmacological, genetic, and behavioral findings indicate
that activation of P2X4 receptor subtype expressed by spinal
microglia is both necessary and sufficient to induce tactile
allodynia after peripheral nerve injury.
Concerning the bidirectional cross talk between activated
microglia and dorsal horn neurons, the chemokine (C-C
motif) ligand 21 (CCL21) released from injured neurons has
been demonstrated to act as an upstream activator of P2X4
receptor [50], in close collaboration with interferon 𝛾, a
cytokine converting resting spinal microglia into its activated
state [51], and tryptase, a protease released from mast cells
that activates proteinase-activated receptor 2 in microglia
[52] (Figure 1). Another critical element for the upregulation
of P2X4 receptors expression is the extracellular matrix
molecule fibronectin, which modulates the transcriptional
and posttranscriptional levels of P2X4 receptor expression
in microglia through the activity of Lyn kinase and the
downstream activation of intracellular signaling pathways
involving phosphatidylinositol 3-kinase- (PI3 K-) Akt and
mitogen-activated protein kinase kinase- (MAPK kinase,
MEK-) extracellular signal-regulated kinase (ERK) [49, 53,
54]. The implications of this wide modulation network
and whether these elements are connected into a common
pathway controlling P2X4 receptor expression are still not
known.
On the other way around, it has been reported that
the activation of microglial P2X4 receptor promoted the
synthesis and release of brain-derived neurotrophic factor
(BDNF), through the activation of p38 MAPkinase [48, 55].
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Figure 1: Central role of microglial P2X4 receptors in mediating a molecular cascade leading to hypersensitivity after peripheral nerve
injury (PNI). The upper left cartoon shows the neuron-to-microglia cross talk triggered by neuronal injury, leading to the appearance of an
“activated” microglia phenotype, which expresses higher levels of the P2X4 receptor. The dotted rectangle is expanded in the lower panel,
showing the complexmolecular network responsible for P2X4 receptor upregulation and involving chemokines, growth factors, and integrins.
Activation of the P2X4 receptor ultimately leads to the recruitment and activation of p38MAP kinase. Reproduced from [56] with permission
from Nature Publishing Group.
BDNF in turn altered the transmembrane anion gradient in a
subpopulation of dorsal horn lamina I neurons, through the
downregulation of the neuronal chloride transporter KCC2.
This makes GABA and glycine act as depolarizing rather
than hyperpolarizing neurotransmitters, causing an aberrant
nociceptive output that contributes to the development of
neuropathic pain [41, 56].
In addition to the P2X4 subtype, microglial cells also
express functional P2X7 receptors. The P2X7 receptor is
a unique member of the P2X receptor family, since it is
only activated by high concentrations of ATP (>100𝜇M)
and can open a much larger membrane pore than any
other P2X channel [57]. Stimulation of P2X7 receptors is
implicated in microglia response to inflammation, release
of proinflammatory cytokines, like IL-1𝛽, and proliferation
[58], underlining the involvement of this receptor subtype in
inflammatory diseases and pain.
Although P2X7 receptors are expressed on a wide variety
of cell types, evidence for involvement of microglial P2X7
receptors in chronic neuropathic pain stems from findings
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that its activation causes the p38 MAPkinase-dependent
release of IL-1𝛽 and cathepsin S, which contribute to the
maintenance of mechanical hypersensitivity in the spinal
cord [59, 60]. Additional hints on the role of P2X7 receptors
in neuropathic pain have been provided by the demonstration
of reduced pain sensitivity in P2X7 receptor-deficient mice
[61] and by the analgesic effects exerted by P2X7 recep-
tor antagonists [62, 63]. In fact, authors demonstrated the
absence of inflammatory and neuropathic hypersensitivity In
fact, inmice lacking the P2X7 receptor, authors demonstrated
the absence of inflammatory and neuropathic hypersensitiv-
ity after both mechanical and thermal stimuli, accompanied
by a reduction of adjuvant-induced increases in IL-1𝛽, IL-6,
IL-10, andmacrophage chemoattractant protein-1, while nor-
mal nociceptive processing is preserved [61]. Moreover, P2X7
receptor was upregulated in human DRG and injured nerves
from chronic neuropathic pain patients [61]. Recent studies
also showed that P2X7 receptor expression is increased in
the ipsilateral spinal cord after sciatic nerve ligation and is
highly restricted tomicroglia; moreover, chronic constriction
injury- (CCI-) induced mechanical allodynia and thermal
hypersensitivity are reversed by intrathecal administration of
the selective P2X7 antagonist Brilliant Blue G [64].
Interestingly, a correlation between single nucleotide
polymorphisms (SNPs) within the coding sequence of the
P2rx7 gene and the sensitivity to chronic pain has been pro-
vided in both mice and humans. In fact, mice in which P2X7
receptors have impaired pore formation due to the P451L
mutation showed less allodynia than mice with the wt pore-
forming P2rx7 allele. Indeed, administration of a peptide,
which blocked pore formation but not cation channel activity,
selectively reduced nerve injury and inflammatory allodynia
only in wt mice. Moreover, in two independent human
chronic pain cohorts, a cohort with pain after mastectomy
and a cohort with osteoarthritis, authors observed a genetic
association between lower pain intensity and the hypofunc-
tional His270 allele of P2X7 receptor, further suggesting that
selectively targeting P2X7 pore formation may be a new
strategy for individualizing the treatment of chronic pain
[65].
Several lines of evidence suggest a functional convergence
between the signaling pathways activated by P2X4 and
P2X7 receptors in microglia. As previously mentioned, p38
MAPkinase is involved in both the P2X4 receptor-mediated
release of BDNF and the P2X7-induced release of IL-1𝛽 and
cathepsin S (see above). Moreover, a recent paper showed
that phosphorylation of p38 MAPK via P2X7 receptor may
induce tactile allodynia/hyperalgesia in an orofacial pain
model based on the CCI of the infraorbital nerve (CCI-ION),
which is most likely mediated by soluble TNF-𝛼 released
by microglia [66]. Thus, activation of p38 MAPK may be
a critical mechanistic step of convergence in the P2X7 and
P2X4 receptor signaling pathways in neuropathic pain. P2X7
and P2X4 receptors also interact to form complexes with
unique channel properties [44, 67].This raises the interesting
possibility that structural and functional interactions, as well
as converging signaling pathways, might be critical cellular
mechanisms that underlie the involvement of microglial
P2X7 andP2X4 receptors in neuropathic pain.The expression
of P2X4 and P2X7 receptors subtype in a variety of cell
types involved in pain transmission represents a promis-
ing target for pharmacological intervention. For example,
locally administered oxidized ATP, an irreversible inhibitor
of P2X7 receptors, had an antihyperalgesic effect on complete
Freund’s adjuvant-induced mechanical hyperalgesia (paw
pressure test) [68].
An important role has been also disclosed for the P2X7
receptor subtype in the modulation of reactive astrogliosis.
Following trauma, an upregulation of its expression on
astrocytes has been demonstrated, and its activation by
extracellular ATP or by synthetic agonists led to the release
of proinflammatory IL-1𝛽, ATP itself, and glutamate [17].
These molecules can further sustain and propagate astrocytic
reaction to injury and can also sensitize nearby neurons
in the spinal cord, thus contributing to nociception. More
recently, the P2X7-mediated astrocytic release of dynorphins
has been demonstrated in the spinal cord [69], thus further
corroborating the notion of a direct involvement of astrocytic
P2X7 receptor subtype in nociception.
The role of glial P2X7 in nociception is not restricted
to the CNS, since recent data established its expression in
SGCs, the specialized population of glial cells that enwrap
neuronal bodies in peripheral sensory ganglia [10]. In sensory
ganglia, ATP released from neuronal somata engages P2X7
receptors expressed by surrounding SGCs [12], which in
turn inhibits back neuronal algogenic P2X3 receptors [70].
Additional P2X receptor subtypes are upregulated in SGCs
upon exposure to proinflammatory conditions [71], but their
role in nociception still remains elusive.
6. G Protein-Coupled Receptors
Activated by Extracellular Nucleotides:
The P2Y Receptor Family
Thefirst P2Y receptor (currently named as the P2Y
1
subtype)
was cloned in 1993 [76, 77], and since then a total of eight
human P2Y receptor subtypes have been identified: the
P2Y
1
, P2Y
2
, P2Y
4
, P2Y
6
, P2Y
11
, P2Y
12
, P2Y
13
, and P2Y
14
receptors [78]. The various P2Y receptor subtypes are func-
tionally coupled to different G proteins, and, consequently,
downstream signaling pathways, either phospholipase C,
with inositol 3 phosphate (IP
3
) formation and intracellular
calcium increase, or adenylyl cyclase, leading to modulation
of cyclic adenosinemonophosphate (cAMP) production [78].
From a pharmacological point of view, P2Y receptors can
be broadly subdivided into four groups based on their
responsivity to nucleotides: (i) adenine nucleotide-preferring
receptors, mainly responding to ADP and ATP; this group
includes human and rodent P2Y
1
, P2Y
12
, and P2Y
13
, and
human P2Y
11
; (ii) uracil nucleotide-preferring receptors,
including the human P2Y
4
and P2Y
6
responding to either
UTP or UDP; (iii) receptors of mixed selectivity (the human
and rodent P2Y
2
, the rodent P2Y
4
and, possibly, P2Y
11
);
and (iv) the P2Y
14
receptor, responding to both UDP and
sugar nucleotides (mainly UDP-glucose and UDP-galactose)
[78, 79].
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7. Glial P2Y Receptors and Chronic Pain:
Still Elusive but Promising Targets for New
Analgesic Strategies
Unlike the key and quite well defined role played by P2X
receptors in pain transmission, controversial information
is currently available concerning P2Y receptor contribution
to nociception. Nevertheless, it is well known that these
receptors are widely expressed by neurons and glial cells in
both the central and the peripheral nervous systems [16], thus
leading to hypothesize that their activity is integrated in the
complexmolecular network associated with the transmission
of nociceptive signals. The comprehension of their role in
pain pathogenesis is therefore of paramount importance for
the discovery of new potential drug targets for pain therapy.
As for P2Y receptors expressed by sensory neurons, the
P2Y
1
receptor subtype is often coexpressed with the P2X3
receptor, acting as its functional antagonist in DRG [80],
while the P2Y
12,13
subtypes can inhibit N-type voltage-gated
calcium channels [81]. Taken together, these data suggest
an overall analgesic profile for ADP-sensitive P2Y receptor
activation. Surprisingly, P2Y
1
receptors were also reported
to mediate hyperalgesia, possibly through the sensitization
of transient receptor potential vanilloid 1 (TRPV
1
) channels
[82], thus suggesting that the functional outcome of P2Y
1
receptor activation could depend upon the specific tissue
conditions. The same hyperalgesic potentiation of TRPV1
receptors has been later demonstrated for the UTP-sensitive
P2Y
2
receptor subtype in rat lumbar DRGs [83].
Increasing evidence is highlighting a role for glial P2Y
receptors in chronic pain. Microglia express a wide range of
P2Y receptors (P2Y
1,2,4,6,12
), with the P2Y
6
and P2Y
12
recep-
tor subtypes mediating chemotaxis and migration towards
the site of damage [43, 84]. To date, only the P2Y
12
receptor
subtype is clearly known to be involved in neuropathic
pain onset. In fact, in response to peripheral nerve injury,
microglial P2Y
12
receptor expression was upregulated, and
its activation was critical for microglial engulfment of
myelinated axons in the spinal dorsal horn [43]. Moreover,
pharmacological blockade, antisense knockdown of P2Y
12
receptor expression, or genetic deletion of the P2ry12 gene
suppresses both mechanical allodynia and thermal hyperal-
gesia in nerve-injured rats [85, 86]. Conversely, intrathecal
administration of the P2Y
12
receptor agonist 2Me-SADP elic-
its pain behavior in na¨ıve rats, mimicking what is observed
in nerve-injured rats [85]. Moreover, mRNA not only for
the P2Y
12
, but also for the P2Y
6,13,14
receptor subtypes
was upregulated in microglia in the ipsilateral spinal cord
following nerve injury, and a mixture of P2Y
6
, P2Y
12
, and
P2Y
13
selective antagonists showed a longer suppressive effect
on pain behavior compared to every single treatment itself
[87].
The P2Y
6
receptor can be considered a sensor for
microglial cell phagocytosis by sensing diffusibleUDP signals
in primary culturedmicroglial cells [84]. Althoughmicroglial
P2Y
6
receptors expression markedly increases in the spinal
cord after peripheral nerve injury [87], its specific role
under neuropathic pain conditions still remains unclear.
As already mentioned, ATP-gated P2X4 receptor channels
expressed in spinal microglia actively participate in central
sensitization, making their functional regulation a key pro-
cess in chronic pain pathologies (see above); interestingly,
it has been recently reported that P2X4 receptors function
is inhibited by the P2Y
6
receptor subtype, highlighting its
possible critical role in regulating neuropathic pain-induced
microglial responses [88].
Although not directly associated with pain signaling to
date, it is conceivable that also P2Y receptors expressed
by astrocytes could significantly contribute to nociception,
especially in the spinal cord. P2Y receptors have been directly
implicated in the modulation of reactive astrogliosis since
the 1990s, also thanks to the contribution of our laboratory
(for reviews, see [9, 89]). In particular, activation of the P2Y
1
receptor subtype has been directly correlated with the release
of prostaglandins and other proinflammatory mediators [90,
91] and directly or indirectly correlated with the transmission
of painful sensations. Targeting astrocytic P2Y receptors
could therefore represent an innovative approach to pain,
specifically neuropathic pain, through the modulation of
astroglial inputs controlling second order spinal neurons
firing.
Very fewdata are currently available on the role of the P2Y
receptor family in SGCs, and the vastmajority of the available
data concerns expression rather than functional studies (for
reviews see [75, 92]). Under basal conditions, SGCs in the
trigeminal ganglion express functional P2Y
1,2,4,6,13
receptor
subtypes [28, 93], whereas glial P2Y expression in DRG cells
has been only evaluated at the mRNA level [94], with the
exception of P2Y
1
receptors protein which has been detected
by immunofluorescence studies [70].
Within the TG, the close interplay between the purinergic
system and other classical pain transducing signals has
been recently elucidated, starting from the observation that
chronic exposure of TG cultures to the algogenic media-
tor bradykinin induced the upregulation of P2Y-mediated
calcium signaling in SGCs [28, 95], thus prompting us to
speculate that P2Y receptors expressed by SGCs could rep-
resent possible pharmacological targets for the development
of innovative therapies against migraine and trigeminal pain
in general (for review see [75]). From then on, in vitro
and in vivo studies have revealed that those specific glial
P2Y receptors potentiated under proalgogenic conditions are
the P2Y
1
and P2Y
2
subtypes (Magni et al., manuscript in
preparation). These results have been partially confirmed by
a recent paper showing that P2Y
2
receptor inhibition induces
analgesia in a rat model of neuropathic pain based on CCI-
ION [96], although authorsmostly focused onP2Y
2
receptors
expressed by trigeminal sensory neurons. Altogether, these
data highlight the key role of P2Y purinergic receptors, and
especially of the P2Y
2
subtype, as promising targets for the
development of new analgesic drugs.
An emerging role for the glial P2Y
12
receptor subtype
has been demonstrated in an animal model of trigeminal
neuropathic pain [97]. In fact, although not expressed in
the TG upon control conditions [14], expression of the
P2Y
12
receptor subtype was detected in activated SGCs after
unilateral lingual nerve crush. Interestingly, administration
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of a P2Y
12
-selective antagonist significantly reverted glial cell
activation and alleviated animals’ sensitivity to mechanical
and heat stimulation of the tongue [97]. These data further
sustain the hypothesis that a shift and/or upregulation in
purinergic receptor expression can be observed within sen-
sory ganglia, and especially on SGCs, upon proalgogenic con-
ditions (Figure 2). This observation opens up the possibility
that drugs selectively targeting specific purinergic receptors
could exert their analgesic activity at the site of receptor
upregulation, thus limiting the occurrence of systemic and
unwanted side effects.
8. Adenosine Exerts Analgesic
Effects through Its Glial Receptors:
An Additional Component of Its
Neuromodulatory Actions
Adenosine is the major metabolite of the ectonucleotidase-
mediated sequential dephosphorylation of ATP. Therefore,
it cannot be classified as a true neurotransmitter, but rather
as a neuromodulator, through the activation of 4 subtypes
of G protein-coupled receptors, that is, the A
1
, A
2A, A2B,
and A
3
adenosine receptor subtypes, collectively referred
to as P1 receptors [98]. The temporal relationship between
ATP release and subsequent adenosine generation from its
hydrolysis guarantees the generation of a feedback inhibitory
loop, which overall counteracts the excitatory effects of ATP.
This is particularly true for the A
1
receptor subtype, which
is coupled with inhibition of cAMP synthesis and with
the activation of potassium conductance, with consequent
inhibition of neuronal firing and neurotransmitter release,
reduction of heart rate, and other inhibitory effects.
A key role for the A
1
receptor subtype in the modulation
of painful sensations has been hypothesized more than 15
years ago. Both spinal and peripheral A
1
receptors have been
found directly involved in the analgesic effects exerted by
several known drugs, like tramadol, acetaminophen, and
amitriptyline, often in close interconnection with 5-HT
7
serotonin receptors [99–101]. Moreover, recent studies also
suggest that the analgesic efficacy of some herbal preparations
long utilized in traditional Chinese medicine can be at least
in part due to a modulation of the adenosine system. In
fact, norisoboldine (the major active alkaloid component
isolated from the dry roots of Lindera aggregata often utilized
for chest and abdomen pain, indigestion, cold hernia, and
frequent urination) was shown to promote analgesia in both
the formalin and the writhing tests in rodents through the
activation of A
1
receptor subtype [102].
The cell population expressing the A
1
receptor subtype
involved in pain transmission was not clearly identified, until
the publication of papers suggesting its microglial identity.
An A
1
receptor subtype selective agonist was in fact shown
to alleviate neuropathic pain and to reduce spinal microglia
activation in the spared nerve injury rat model [103]. Most
interestingly, authors later demonstrated that exposure to
proalgogenic ATP induced a significant increase in A
1
recep-
tor subtype expression in microglia, whose activation in turn
led to inhibition of microglial phenotypic changes and to the
reduction of the ability of microglia to promote neuronal
firing [104]. Thus, it can be envisaged that microglial A
1
receptors are upregulated and engaged to counteract the
algogenic actions induced by massive ATP release at injury
or inflammation sites.
The role of additional adenosine receptor subtypes in
nociception is much less clear. Conflicting results have been
obtained by administering either A
2A receptor subtype-
selective agonists or antagonists in animal pain models,
showing both analgesia and hyperalgesia [105]. In fact, it
has been demonstrated that A
2A receptor knock-out mice
have a reduced sensitivity to pronociceptive stimuli, which
seems to be mediated by the loss of pronociceptive A
2A
receptors on DRG primary sensory neurons [106]. It should
bementioned, however, that microglia express A
2A receptors,
which are directly involved in the modulation of the release
of proalgogenic stimuli, like nerve growth factor (NGF),
prostaglandin E2 (PGE
2
), and nitric oxide (NO) [107]. Based
on the above-mentioned data, it can therefore be envisaged
that selective A
2A receptor antagonists could counteract the
proinflammatory and proalgogenic features of microglial
cells and ultimately prove to be useful as antialgogenic agents,
at least in inflammatory pain conditions. Conversely, the
intrathecal injection of a selective A
2A receptor agonist pro-
duced a significant and long-lasting reversal of mechanical
allodynia and thermal hyperalgesia consequent to the CCI
of the sciatic nerve [108]. A reduction of glial cell activation
and a significant upregulation in the production of anti-
inflammatory IL-10 in the spinal cord were also observed,
thus suggesting that activating rather than inhibiting the
A
2A receptor subtype could represent a better option for
neuropathic pain states [108].
Finally, the availability of selective agonist ligands has
allowed demonstrating an antialgogenic role for theA
3
recep-
tor subtype in neuropathic pain induced either by the CCI of
the sciatic nerve or by chemotherapic agents in rodents [109].
The cellular localization of the target receptors involved in
nociception has not been directly identified, although it has
been demonstrated that theA
3
receptor subtype is involved in
ADP-mediated microglia chemotaxis and process extension
[110].
Although their direct role in pain transmission has not
been proven yet, it is worth mentioning that all the four
adenosine receptor subtypes are expressed by spinal cord and
brain astrocytes and significantly contribute to the modula-
tion of reactive astrogliosis (for review see [111]). It is therefore
conceivable that they can participate to astrocyticmodulation
of neuronal functions, especially under chronic pain condi-
tions, when high amounts of adenosine are produced as a
consequence of the hydrolysis of extracellular nucleotides and
of the leakage of nucleic acids from damaged cells [111]. To
date the role of adenosine receptors in peripheral ganglia has
not been studied in detail.
A major limitation to the systemic use of drugs acting
on adenosine receptors is represented by their wide dis-
tribution, especially in the CNS and in the cardiovascular
system, which could account for significant and harmful side
effects. Specifically, activation of the A
1
adenosine receptors
in the CNS could lead to inhibition of locomotor activity
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Figure 2: Plasticity of purinergic signaling within sensory ganglia upon proinflammatory conditions.The cartoon schematically summarizes
currently available data on the modulation of P2 receptor expression by proalgogenic and proinflammatory conditions in sensory ganglia.
An increased line weight indicates receptor upregulation, which has been observed in both sensory neurons and surrounding satellite glial
cells. Some receptor subtypes (i.e., glial P2Y
12
receptor subtype) are only detected upon algogenic conditions. Activation of P2 receptors
by extracellular nucleotides leads to the modulation of other systems involved in nociception, like TRPV1 receptors, and in the release
of additional cytokines, growth factors, and other substances (see box), further contributing to the development and maintenance of a
proalgogenic milieu. Reproduced from [75] with permission from Elsevier.
and catalepsy, whereas in the heart severe bradycardia and
atrioventricular block may occur [112]. Acting on the A
2A
subtype with selective agonists may lead to a significant
drop in blood pressure, accompanied by tachycardia [112].
Conversely, despite the significant increase of circulating
histamine that was observed in mice, clinical studies in
cancer patients have shown no significant side effects after
administration of selective A
3
receptor agonists [112].
9. When Will an Analgesic Drug
Targeting Glial Purinergic Receptors Be
Finally Available?
The incomplete and still growing list of scientific studies
reviewed in this paper clearly demonstrates that targeting
glial purinergic receptors might significantly improve the
currently available armamentarium of analgesic drugs to
be utilized in chronic pain state, still lacking a satisfac-
tory pharmacological control. Nevertheless, to date no new
purinergic drug entities have reached the market. This is
mostly due to (i) the widespread expression of all the different
receptor subtypes, which renders the discrimination between
beneficial and side effects extremely complicated, (ii) the lack
of good subtype-selective agents, and (iii) when selective
ligands are available, the lack of an acceptable route of
administration to humans.
Concerning the most studied purinergic receptor in
nociception, the neuronal P2X3 subtype, no clinical studies
were available so far, despite the massive preclinical in vivo
and in vitro efforts.Thiswasmainly due to the lack of selective
antagonists with a chemical structure suitable for administra-
tion to humans [37]. Very recently, however, two clinical trials
employing the new orally active P2X3-selective antagonist
AF-219 [113] were concluded (see Table 1), although results
have not been disclosed yet. Recently, the extensive use of
high-throughput screening followed by a hit-to-lead program
has prompted a number of pharmaceutical companies to
identify highly selective, potent, and metabolically stable
small-molecule inhibitors for both P2X4 and P2X7 receptor,
which provide a novel therapeutic approach to the treatment
of pain and inflammatory disorders [114, 115]. Nevertheless,
no significant results have emerged from the first clinical
trials performed with different P2X7-selective antagonists
(Table 1), thus suggesting that the role of this receptor subtype
should be reconsidered, at least in rheumatoid arthritis-
related pain.
As for P2Y receptors, although important progress in
exploring structure-activity relationships has been recently
achieved with the publication of the first crystal structure of a
member of the family [116],most of the P2Y receptor subtypes
are still lacking potent and selective synthetic agonists and
antagonists [78], which has greatly hampered both research
in this field, and the translation of in vitro data to in vivo and
clinical settings. Additionally, the only P2Y-selective antago-
nists available so far, acting on the P2Y
12
receptor subtype,
are widely utilized for their strong antiplatelet activity [116],
which poses serious concerns about possible side effects in
case of their administration for painful conditions.
Finally, in the case of the A
1
adenosine receptor subtype,
its widespread distribution has greatly limited the preclinical
and clinical use of the available A
1
-selective agonists, due
to significant systemic side effects (see above). Recently, it
has been demonstrated that a novel and potent A
1
receptor
allosteric modulator, named TRR469, exhibits antinocicep-
tive activity in the formalin and writhing tests in mice,
without showing the usual side effects of A
1
-selective agonists
(see above) [117].
It is also worth reaffirming that expression of purinergic
receptor on glial cells is highly plastic and can therefore
significantly change during the course of chronic pain con-
ditions (Figure 2). For example, it has been hypothesized that
the purinergic system is fundamental for the so-called “modal
shift” of microglia, namely, their acquisition of different
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Table 1: Summary of past and current clinical trials evaluating purinergic ligands in pain.
Name of ligand Company Clinical trialnumber Type of pain Main outcomes
AF219
(P2X3 antagonist)
Afferent
Pharmaceuticals
NCT01554579 Osteoarthritis of the knee No published results yet
NCT01569438 Interstitial cystitis/bladderpain syndrome No published results yet
CE-224,535
(P2X7 antagonist) Pfizer
NCT00628095 Rheumatoid arthritis
CE-224,535 was not efficacious,
compared with placebo, for the
treatment of RA in patients with an
inadequate response to metotrexate
[72]
NCT00418782 Osteoarthritis of the knee
CE-224,535 failed to demonstrate
efficacy in a 2-week study of knee
pain in osteoarthritis patients
AZD9056 AstraZeneca NCT00520572 Rheumatoid arthritis AZD9056 does not have significantefficacy in the treatment of RA [73]
GSK1482160
(P2X7 antagonist) GlaxoSmithKline NCT00849134
“First-in-human” study to
assess the pharmacokinetic
profile of the drug
No major safety or tolerability
concerns were identified in this study.
Nevertheless, monitoring the release
of IL-1𝛽 in subjects led to the decision
to discontinue drug development for
inflammatory pain conditions [74]
Adenosine
(e.v.)
Wake Forest School
of Medicine NCT00349921
Neuropathic pain
(comparison with clonidine) No published results yet
Xsira
Pharmaceuticals NCT00298636
Perioperative pain
(hysterectomy/myomectomy) No published results yet
GW493838 GlaxoSmithKline NCT00376454
Neuropathic pain as a result of
postherpetic neuralgia or
nerve injury
No published results yet
phenotypes over time, based on the time-dependent modi-
fication of the expression profile of P1 and P2 receptors [118].
This additional fascinating, but complicating, issue should
be taken into consideration when deciding which is the best
target option for the development of an antihyperalgesic
rather than an antiallodynic purinergic-based agent.
Therefore, based on these promises and pitfalls, a closer
collaboration among pharmacology, biochemistry, molecular
biology, and pharmaceutical chemistry is highly recom-
mended to clearly identify and target the most promising
“druggable” receptors, which could be successfully utilized
in preclinical and clinical studies to accelerate the process
towards new therapeutic options for chronic pain patients.
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